What is the price of CStone Pharmaceuticals Platinib?

CStone Pharmaceuticals’ Pralsetinib (Pralsetinib) has been used clinically. Platinib is an oral, potent and highly selective investigational drug that targets oncogenic RET mutations, developed by CStone's strategic partner Blueprint Medicines. CStone holds exclusive development and commercialization rights for platinib in Greater China.

In March 2021, China's National Medical Products Administration approved platinib as a national Class I new drug for the treatment of adult patients with rearranged transfection (RET) gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-containing chemotherapy. Platinib became the first RET inhibitor approved for marketing in China, and it was also the first domestic drug approved using real-world data (RWD) to assist clinical evaluation. In clinical trials in the United States, platinib has also shown efficacy in patients with RET fusion-positive non-small cell lung cancer and advanced or metastatic RET fusion-positive thyroid cancer that requires systemic therapy and is refractory to radioactive iodine. Therefore, platinib is already in clinical use and provides a new treatment option for some lung cancer patients.

Currently, the original drug Platinib on the market in China is relatively expensive, and the purchase conditions are also relatively difficult. The price is tens of thousands of yuan. At the same time, because Platinib has not yet been included in medical insurance, patients need to pay the full amount out of their own pocket. This is also one of the important factors that patients need to consider when purchasing. However, there are also some relatively lower-priced versions. For example, the price of generic platinib sold overseas may be several thousand yuan, and it will also be affected by exchange rates.